

BEST AVAILABLE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Application of: Haim AVIV et al. Confirmation No.: 6729
Application No.: 10/644,687 Group Art Unit: 1626
Filed: August 19, 2003 Examiner: T.A. Solola
For: HIGH ENANTIOMERIC PURITY Attorney Docket No.: 87754-7500
DEXANABINOL FOR
PHARMACEUTICAL COMPOSITIONS

DECLARATION OF RAPHAEL MECHOULAM UNDER 37 C.F.R. § 1.132

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. I am a co-inventor, together with Jeffery J. Feigenbaum, Naftali Lander and Morris Srebnik, of U.S. Patent No. 4,876,276 which claims the compound HU-211, the full chemical name of which is 1,1-dimethylheptyl-(3S,4S)-7- hydroxy-delta⁶-tetrahydrocannabinol, subsequently assigned the trivial chemical name dexanabinol. I am a citizen of Israel and currently reside at 12 Tchernibovsky Street, Jerusalem 92581, Israel.


2. I received my Ph.D. degree from the Weizmann Institute of Science, Rehovot, Israel, in 1958. I have worked in research in the Hebrew University of Jerusalem since 1966. I was a full professor in the School of Pharmacy of the Hebrew University of Jerusalem from 1972, until I retired in 2003. As a professor emeritus, I continue to do research at the Hebrew University.

3. I was the Lionel Jacobson Professor of Medicinal Chemistry at the Hebrew University of Jerusalem, for almost thirty years. I have over forty years of experience in the research, synthesis, testing, and development of new compounds, compositions, and methods of making and using the same. Since the beginning of my career, I have published almost 300 scientific articles in highly regarded journals and books, and

have presented my achievements at many international scientific conferences. Most of these publications deal with chemistry, pharmacology and clinical effects of plant, synthetic and mammalian cannabinoids. I was the first to identify the psychotropically active constituent in marijuana (delta-9-tetrahydrocannabinol) as well as the first active endocannabinoid in brain (anandamide). I am a member of several scientific societies and was elected a member of the Israel Academy of Sciences in 1994. I have received numerous local and international prizes. Attached are my curriculum vitae and list of publications.

4. I have reviewed and understand the above-identified patent application, the pending claims, the Office Action, and the reference cited therein. In particular, I am a co-inventor of U.S. Patent No. 5,284,867 to Kloog et al., a patent that I understand has been cited against the claims of the above-identified application.

5. The above-identified application is directed to a compound, or pharmaceutically acceptable salt, ester, or solvate thereof, having the formula:



having the (3S,4S) configuration and being in enantiomeric excess of at least 99.90% over the (3R,4R) enantiomer. The application further relates to compositions comprising the compound and uses thereof. The above-identified application further provides a large-scale synthetic procedure for the preparation of dexanabinol, HU-211, and a new analytical method for the determination of the amount of the enantiomer HU-210, which allows for the accurate evaluation of the enantiomeric excess of dexanabinol.

6. The Kloog et al. patent does not teach the preparation of HU-211, nor the enantiomeric excess that are currently claimed. Rather, Kloog et al. discloses new uses of previously known compounds in particular of HU-211. The synthesis of HU-211 was

disclosed in U.S. Patent No. 4,876,276, for which I am a co-inventor. In U.S. Patent No. 5,284,867 to Kloog et al., as well as in U.S. Patent No. 4,876,276 to Mechoulam et al. wherein HU-211 is first disclosed, the phraseology used in connection with enantiomeric purity is "essentially free of the (3R,4R) enantiomer", which is defined by the fact that the claimed compounds are devoid of any undesired cannabimimetic psychotropic side effects, at the doses tested.

7. The Examiner asserts that absent of showing to the contrary, the phraseology "essentially free of the (3R,4R) enantiomer" anticipates the present claims wherein the (3S,4S) enantiomer is in enantiomeric excess of at least 99.90% over the (3R,4R) enantiomer. I have been asked to give my opinion regarding the superior enantiomeric purity of the claimed compound in the present application.

8. At the time we filed the application serial number 112,705 relating to dexanabinol, which issued as U.S. Patent No. 4,876,276, the enantiomeric purity was achieved due to crystallinity of intermediate compound V, 4-oxomyrtenyl pivalate. We had no direct analytical method to measure the amount of HU-210 and we were not able to determine mathematically the enantiomeric purity of dexanabinol. The sole assay available at the time was functional and the presence of excess amount of HU-210 was detected using the tetrad assay. This method tests four different parameters in rodents and is designed to monitor cannabimimetic effects in a given preparation. Such an assay does not reveal the degree of absolute purity of the compound nor its enantiomeric excess.

9. In our article entitled "Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivatives" published in Tetrahedron Assymetry 1(5): 315-318 (1990), we disclosed some information concerning the enantiomeric excess of dexanabinol (HU-211) over its enantiomer HU-210. A copy of this article is attached hereto. We followed a slightly improved synthetic process, as compared to U.S. Patent No. 4,876,276, wherein the desired enantiomer of 4-oxomyrtenyl pivalate was first isolated by chromatography, then crystallized from pentane, and wherein dexanabinol was thrice recrystallized from pentane. After this synthesis, we did not directly assess the amount of HU-211 by reverse phase HPLC and of HU-210 by chiral HPLC, but of their substituted bis (MTPA) esters. There is no certainty that derivatization was of equal efficacy for each of the enantiomer and it is possible that the relative amount of the derivatized

enantiomers does not correlate with the relative amount of the original underderivatized enantiomers as accurately assessed using the analytical methods disclosed in the present application. Even if we assume that the enantiomeric excess of 99.8% we reported for the derivatized enantiomers reflected the true enantiomeric excess of the original enantiomers, it is our opinion that the absolute purity of dexanabinol *per se* was below the value of at least 98% and the amount of HU-210 in the preparation was above the value of at least 0.05%. These threshold values, indicated in Table 1 of the present application, were achieved following the synthetic procedures disclosed in the present application.

10. The compound of Kloog et al. does not have an enantiomeric excess of at least 99.9% of the (3S,4S) enantiomer over the (3R,4R) enantiomer, as required by the instant claims. In fact, as we understand, the compound of Kloog et al. is at most as pure as the dexanabinol disclosed in the aforementioned article which, as detailed above, does not disclose a highly pure dexanabinol as required by the present application nor the enantiomeric excess of the unmodified enantiomers.

11. We never synthesized dexanabinol in amounts above laboratory scale, nor have we synthesized pharmaceutical grade dexanabinol intended for human use. We have not developed a synthetic procedure for commercial scale or clinical purposes and have not used during the course of our research analytical methods that directly assessed and quantified the amount of the separate enantiomers. The enantiomeric excess values reported by us, were calculated based on the peak area of the derivatized HU-211 and HU-210, and not as disclosed in the present application based on the standardized calculated amount of each of the underderivatized enantiomers.

12. We are aware that the applicant has invested time and resources to improve these initial results by modifying the original procedures. These modifications lead to the development of the current synthetic process and improved analytical methods of the present application, that enable the preparation of dexanabinol of the claimed enantiomeric excess.

13. As one of skill in the art, based on my review of the claimed invention and of the closest prior art, it is my opinion and judgment that the invention as currently claimed provides dexanabinol with superior properties. In particular, the advantage of the

synthetic process, which is adapted to large scale synthesis, and the superiority of the analytical methods, which allow accurate determination of the enantiomeric excess, lead to the preparation of a drug substance appropriate for human use.

14. I further declare that all statements made herein of my knowledge are true and all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Dated: March 9, 2005

R. Mechoulam

Printed Name: Raphael Mechoulam
Title: Professor Emeritus of Medicinal Chemistry
at The Hebrew University of Jerusalem

Professor Raphael Mechoulam

1930	Born Sofia, Bulgaria
1952	M.Sc. in Biochemistry, Hebrew University, Jerusalem
1953-56	Army Service
1956-58	Ph.D. studies with Professor F. Sondheimer, Weizmann Institute, Rehovot. Research on steroid synthesis.
1959-60	Postdoctoral research at Rockefeller Institute, New York. Research on the structure of triterpenes.
1960-65	Junior and later Senior Scientist, Weizmann Institute. Research on chemistry of natural products, including cannabinoids, terpenes, alkaloids.
1966-	Hebrew University, Jerusalem; 1968 – Associate Professor; 1972 – Professor.
1975-	Endowed chair: Lionel Jacobson Professor of Medicinal Chemistry.
1979-82	Rector (Academic Head) of Hebrew University.
1983-85	Pro-Rector, Hebrew University.
1993-94	Visiting Professor, Department of Pharmacology, Medical College of Richmond.
1999-2000	President of the International Cannabinoid Research Society.

Research interests: chemistry and biological activity of natural products and synthetic drugs.

<u>Honors</u>	Somach Sachs Prize for “best research by a scientist below 35 at the Weizmann Institute”, 1964.
	Distinguished Visiting Professorship, Ohio State University, Columbus, Ohio, 1982-1983.
	International Biannual Cannabis meeting (held in Colymbari, Crete), 1990, dedicated to R.M.
	“Pharmacology, Biochemistry and Behavior” Nov. 1991 issue dedicated to R.M. for achievements in the cannabinoid field.
	Kolthof Prize in Chemistry, 1994, The Technion, Haifa.
	Elected, Member Israel Academy of Sciences, 1994.

Hanf prize, Germany, 1997, for “the discovery of THC and lasting research on Cannabis – anandamides”.

Hanus Medal, 1998, by Czech Chemical Society in recognition of contribution to cannabinoid chemistry.

David R. Bloom Prize, 1998, for “excellence in pharmaceutical research”, Hebrew University.

The International Cannabinoid Research Society (ICRS) establishes an annual award to be named The R. Mechoulam Annual Award in Cannabinoid Research, 1999.

Israel Prize in Exact Sciences – chemistry, 2000.

Ariens Award and Lecture. 2000. Dutch Pharmacological Society sponsored by Solvay Pharmaceuticals. Amsterdam.

Honorary Degree Doctor of Science.
Ohio State University, Columbus, Ohio, 2001.

Elected, Honorary Member of the Israel Society of Physiology and Pharmacology, 2002.

Heinrich Wieland Prize, endowed by Boehringer-Ingelheim, to promote research on “lipids and related substances in the fields of Chemistry, Biochemistry, Physiology, and Clinical Medicine”, Germany, 2004.

Name lectures:

Copenhagen, Denmark, 1977, Ferosan Lecture, School of Pharmacy.

Tuscon, Arizona, 1983, Golden Headed Cane Memorial Lecture, Faculty of Medicine.

Stockholm, Sweden, 1994, Ulf von Euler Lecture in Physiology, Karolinska Institute.

Maale Hamisha, 2000, Magnes Memorial Lecture, Israel Society for Physiology and Pharmacology.

R. Mechoulam.

List of publications

Summaries of lectures at scientific meetings are not included.

1. S. Reuter, S. Cohen, R. Mechoulam, A. Kaluszyner and A.S. Tabori. On the mechanisms of DDT resistance. *Rivista di Parasitologia*, 17, 125-127 (1956).
2. R. Mechoulam, S. Cohen and A. Kaluszyner. Basic alcoholysis of the trifluoromethyl group in 1,1,1-trifluoro-2,2-diarylethenes. *J. Org. Chem.*, 21, 801-802 (1956).
3. F. Sondheimer and R. Mechoulam. Synthesis of steroidal methylene compounds by the Wittig reaction. *J. Amer. Chem. Soc.*, 79, 5029-5033 (1957).
4. S. Cohen, A. Kaluszyner and R. Mechoulam. On the fluorination of DDT with HF and HgO. *J. Amer. Chem. Soc.*, 79, 5979-5981 (1957).
5. A. Kaluszyner, R. Mechoulam and M. Breuer. Urea and thiourea derivatives for larvical testing. *Bull. Research Council Israel*, 7A, 135-137 (1958).
6. E.D. Bergmann, Z.H. Levinson and R. Mechoulam. The toxicity of Veratrum and Solanum alkaloids to housefly larvae. *J. Insect Physiol.*, 2, 162-177 (1958).
7. F. Sondheimer and R. Mechoulam. Further aspects on the Wittig reaction in the steroid series. 20-dehydro-cholesterol. *J. Amer. Chem. Soc.*, 80, 3087-3090 (1958).
8. R. Mechoulam and F. Sondheimer. The Wittig reaction with fluorenone. Formation of cyclopropane derivatives. *J. Amer. Chem. Soc.*, 80, 4386-4388 (1958).
9. F. Sondheimer and R. Mechoulam. The Diels-Alder reaction of steroidal 20-methylene- Δ^{16} -pregnene derivatives with maleic anhydride. *J. Org. Chem.*, 24, 106-107 (1959).
10. F. Sondheimer, S. Burstein and R. Mechoulam. Synthesis in the cardiac aglycone field. The conversion of 14 α to a 14 β hydroxy

group in the androstane series. The ultraviolet spectra of Δ^{15} -androstene-17-ones. *J. Amer. Chem. Soc.*, 82, 3209-3214 (1961).

11. F. Sondheimer, R. Mechoulam and M. Shprecher. 19-Hydroxy-10-isotestosterone. *Tetrahedron Letters*, 38-44 (1960).
12. R. Mechoulam, F. Sondheimer, A. Melera and F.A. Kincl. The structure of zapotidine. *J. Amer. Chem. Soc.* 83, 2022 (1961).
13. R. Mechoulam. Stereochemistry of ceanothic (emmolic) acid. *Chemistry and Industry*, 1835-1836 (1961).
14. R. Mechoulam. The structure of ceanothic acid. *J. Org. Chem.*, 27, 4070-4073 (1962).
15. R. Mechoulam, N. Daniely and Y. Mazur. The structure and synthesis of oleuropeic acid. *Tetrahedron Letters*, 709-712 (1962).
16. R. Mechoulam and Y. Gaoni. The structure of dihydronicotyrine. *Rec. Trav. Chim. Pays-Bas*, 82, 1159-1162 (1963).
17. R. Mechoulam and Y. Shvo. The structure of cannabidiol. *Tetrahedron*, 19, 2073-2078 (1963).
18. Y. Gaoni and R. Mechoulam. The structure and synthesis of cannabigerol, a new hashish constituent. *Proc. Chem. Soc.*, 82 (1964).
19. Y. Gaoni and R. Mechoulam. Isolation, structure and partial synthesis of an active constituent of hashish. *J. Amer. Chem. Soc.*, 86, 1646-1647 (1964).
20. S.W. Pelletier, N. Adityachaudhury, M. Tomasz, J.J. Reynolds and R. Mechoulam. Senegenic acid, a pentacyclic nor-triterpene acid. *Tetrahedron Letters*, 3065-3070 (1964).
21. F. Sonheimer, R. Mechoulam and M. Shprecher. The synthesis of 19-hydroxy-10-isotestosterone. *Tetrahedron* 20, 2473-2485 (1964).
22. R. Mechoulam and Y. Gaoni. The isolation and structure of cannabinolic, cannabidiolic and cannabigerolic acids. *Tetrahedron*, 21, 1223-1229 (1965).

23. H. Budzikiewicz, R.T. Aplin, D.A. Lightner, C. Djerassi, R. Mechoulam and Y. Gaoni. Massenspektroskopische Untersuchung der Inhaltstoffe von Haschisch. *Tetrahedron*, 21, 1881-1888 (1965).
24. R. Mechoulam and Y. Gaoni. A total synthesis of dl- Δ^1 -tetrahydrocannabinol, the active constituent of hashish. *J. Amer. Chem. Soc.*, 87, 3273-3275 (1965).
25. S.W. Pelletier, N. Adityachaudhury, M. Tomaz, J.J. Reynolds and R. Mechoulam. The structure of senegenic acid, a nortriterpene artifact from *Polygala senega*. *J. Org. Chem.*, 30, 4234-4247 (1965).
26. Y. Gaoni and R. Mechoulam. The isomerization of cannabidiol to tetrahydrocannabinols. *Tetrahedron*, 22, 1481-1488 (1966).
27. Y. Gaoni and R. Mechoulam. Cannabichromene, a new active principle in hashish. *Chem. Comm.*, 20-21 (1966).
28. Y. Gaoni and R. Mechoulam. Concerning the isomerization of Δ^1 to Δ^6 -tetrahydrocannabinol. *J. Amer. Chem. Soc.*, 88, 5673-5675 (1966).
29. R. Mechoulam and A. Hirshfeld. The synthesis of zapotidine. *Tetrahedron*, 23, 239-242 (1967).
30. R. Mechoulam and Y. Gaoni. The absolute configuration of Δ^1 -tetrahydrocannabinol, the major active constituent of hashish. *Tetrahedron Letters*, 1109-1111 (1967).
31. R. Mechoulam, P. Braun and Y. Gaoni. A stereospecific synthesis of (-)- Δ^1 and (-)- Δ^6 -tetrahydrocannabinols. *J. Amer. Chem. Soc.*, 89, 4552-4554 (1967).
32. R. Mechoulam and Y. Gaoni. Recent advances in the chemistry of hashish, Review article. *Progress in the Chemistry of Organic Natural Products. (Fortschritte der Chemie Organischer Naturstoffe)* ed. by L. Zechmeister, XXV, 175-213 (1967).
33. R. Mechoulam, B. Yagnitinsky and Y. Gaoni. Stereoelectronic factor in the chloranil dehydrogenation of cannabinoids. Total Synthesis of d,l-cannabichromene. *J. Amer. Chem. Soc.*, 90, 2418-2420 (1968).

34. S. Burstein and R. Mechoulam. Stereospecifically labelled Δ^6 -tetrahydrocannabinol. *J. Amer. Chem. Soc.*, 90, 2420 (1968).
35. J.J. Bicher and R. Mechoulam. Pharmacological effects of two active constituents of marihuana. *Arch. Intern. Pharmacodyn.*, 172, 24-31 (1968).
36. R. Mechoulam, Z. Ben-Zvi and Y. Gaoni. On the nature of the Beam test. *Tetrahedron*, 24, 5615-5624 (1968).
37. Y. Gaoni and R. Mechoulam. The iso-tetrahydrocannabinols. *Isr. J. Chem.*, 6, 679-690 (1968).
38. L. Crombie, R. Ponsfort, A. Shani, B. Yagnitinsky and R. Mechoulam. Hashish components. Photochemical production of cannabicyclol from cannabichromene. *Tetrahedron Letters*, 5771-5772 (1968).
39. R. Mechoulam. Tetrazolo-steroids. *Isr. J. Chem.*, 6, 909-916 (1968).
40. R. Mechoulam and Z. Ben-Zvi. Carboxylation of resorcinols with methyl magnesium carbonate. Synthesis of cannabinoid acids. *Chem. Commun.*, 343-344 (1969).
41. R. Mechoulam, Z. Ben-Zvi, B. Yagnitinsky and A. Shani. A new tetrahydrocannabinolic acid. *Tetrahedron Letters*, 2339-2341 (1969).
42. R. Mechoulam and B. Yagen. Stereoselective cyclization of cannabinoid 1,5 dienes. *Tetrahedron Letters*, 5349-5352 (1969).
43. B. Yagen and R. Mechoulam. Stereospecific cyclizations and isomerizations of cannabichromene and related cannabinoids. *Tetrahedron Letters*, 5353-5356 (1969).
44. S.H. Burstein, F. Menezes, E. Williamson and R. Mechoulam. Metabolism of Δ^6 -tetrahydrocannabinol, an active marihuana constituent. *Nature*, 225, 87-88 (1970).
45. A. Shani and R. Mechoulam. A new type of cannabinoids. Syntheses of cannabielsoic acids by a novel photooxidative cyclization. *Chem. Comm.*, 273-274 (1970).

46. Z. Ben-Zvi, R. Mechoulam and S. Burstein. Identification through synthesis of an active Δ^6 -tetrahydrocannabinol metabolite. *J. Am. Chem. Soc.*, 92, 3468-3469 (1970).

47. R. Mechoulam. Marihuana chemistry. Review. *Science*, 168, 1159- 1166 (1970).

48. R. Mechoulam, A. Shani, B. Yagnitinsky, Z. Ben-Zvi, P. Braun and Y. Gaoni. Some aspects of cannabinoid chemistry in "Botany and Chemistry of Cannabis" p. 93-117. (Ed. C.R.B. Joyce and S.H. Curry) Churchill, London.

49. B. Eckstein, R. Mechoulam and S.H. Burstein. The identification of 5α -androstane- 3α , 17β -diol as a major metabolite of pregnenolone in rat ovary at the onset of puberty. *Nature*, 228, 866-868 (1970).

50. R. Mechoulam, A. Shani, H. Edery and Y. Grunfeld. The chemical basis of hashish activity. *Science*, 169, 611-612 (1970).

51. Z. Ben-Zvi, R. Mechoulam and S.H. Burstein. Synthesis of $\Delta^1(6)$ -THC metabolites. *Tetrahedron Letters*, 4495-4497 (1970).

52. Y. Gaoni and R. Mechoulam. The isolation and structure of Δ^1 -THC and other neutral cannabinoids from hashish. *J. Am. Chem. Soc.*, 93, 217-224 (1971).

53. A. Shani and R. Mechoulam. Photochemical reactions of cannabidiol. Cyclization to Δ^1 -THC and other transformations. *Tetrahedron*, 27, 601-606 (1971).

54. H. Edery, Y. Grunfeld, Z. Ben-Zvi and R. Mechoulam. Structural requirements for cannabinoid activity. *Ann. N.Y. Acad. Sci.*, 191, 40-53 (1971).

55. Z. Ben-Zvi, R. Mechoulam, H. Edery and G. Porath. 6β -hydroxy- Δ^1 -tetrahydrocannabinol. Synthesis and biological activity. *Science*, 174, 951-952 (1971).

56. R. Mechoulam, P. Braun and Y. Gaoni. Syntheses of Δ^1 -THC and related cannabinoids. *J. Am. Chem. Soc.*, 94, 6159-6165 (1972).

57. J.L.G. Nilsson, I.M. Nilsson, S. Agurell, Z. Ben-Zvi and R. Mechoulam. Synthesis of a potential urinary THC metabolite. *Acta Pharm. Suec.*, 9, 215-220 (1972).

58. H. Edery, Y. Grunfeld, G. Porath, Z. Ben-Zvi, A. Shani and R. Mechoulam. Structure activity relationships in the THC series. Modifications on the aromatic ring and on the side chain. *Arzneim. Forsch.*, 22, 1995-2003 (1973).

59. R. Mechoulam, H. Varconi, Z. Ben-Zvi, H. Edery and Y. Grunfeld. Synthesis and biological activity of five tetrahydrocannabinol metabolites. *J. Am. Chem. Soc.*, 94, 7930-7931 (1972).

60. R. Mechoulam, Z. Ben-Zvi, A. Shani, H. Zemler, S. Levy, H. Edery and Y. Grunfeld. "Cannabinoids and Cannabis Activity" in "Cannabis and its Derivatives. Pharmacology and Experimental Psychology". (Eds. W.D.M. Paton and J. Crown), Oxford University Press, 1972, p. 1-15.

61. R. Mechoulam, ed. "Marijuana. Chemistry, Metabolism, Pharmacology and Clinical Effects". Academic Press, New York, 1973.

Two chapters were authored by R. Mechoulam:

- a) Cannabinoid Chemistry – R. Mechoulam, pp. 1-99
- b) Structure-Activity Relationships in the Cannabinoid Series – R. Mechoulam and H. Edery, pp. 101-136.

62. R. Mechoulam, Z. Ben-Zvi, H. Varconi and Y. Samuelov. Cannabinoid rearrangements. Synthesis of Δ^5 -tetrahydrocannabinol. *Tetrahedron*, 29, 1615-1619 (1973).

63. I.M. Nilsson, S. Agurell, J.L.G. Nilsson, A. Ohlsson, J.E. Lindgren and R. Mechoulam. Metabolism of 7-hydroxy- $\Delta^1(6)$ -tetrahydrocannabinol in the rabbit. *Acta Pharm. Suec.*, 10, 97-106 (1973).

64. R. Mechoulam, Z. Ben-Zvi, S. Agurell, I.M. Nilsson, J.L.G. Nilsson, H. Edery and Y. Grunfeld. Δ^6 -Tetrahydrocannabinol-7-oic acid, a urinary Δ^6 -THC metabolite: isolation and synthesis. *Experientia*, 29, 1193-1195 (1973).

65. R. Mechoulam. Chemistry and Canabis activity. *Ciencia e Cultura, Brasil*, 25, 742-747 (1973).

66. S. Houry, R. Mechoulam, P.J. Fowler, E. Macko and B. Loev. Benzoxocin and benzoxonin derivatives: Novel groups of terpenophenols with central nervous system activity. *J. Med. Chem.*, 17, 287-293 (1974).

67. A. Shani and R. Mechoulam. Cannabielsoic acids. Isolation and synthesis by a novel oxidative cyclization. *Tetrahedron*, 30, 2437-2446 (1974).

68. R. Mechoulam, K. Luchter and A. Goldblum. A new method for the oxidation of monoketones to 1,3 diketones. *Synthesis*, 363-364 (1974).

69. S.P. Banerjee, S.H. Snyder and R. Mechoulam. Cannabinoids: Influence on neurotransmitter uptake in rat brain synaptosomes. *J. Pharmacol. Exp. Therap.*, 194, 74-81 (1975).

70. N.K. McCallum, B. Yagen, S. Levy and R. Mechoulam. Cannabinol: a rapidly formed metabolite of Δ^1 - and Δ^6 -tetrahydrocannabinol. *Experientia*, 31, 520-521 (1975).

71. M. Cais, S. Dani, Y. Josephy, A. Nodiano, L. Snarsky, H. Gershon and R. Mechoulam. A free radical immunoassay for cannabinoid metabolites. *FEBS Letters*, 55, 257-260 (1975).

72. E.A. Carlini, R. Mechoulam and N. Lander. Anticonvulsant activity of four oxygenated cannabidiol derivatives. *Res. Commun. Chem. Pathol. Pharmacol.*, 12, 1-15 (1975).

73. S. Houry, R. Mechoulam and B. Loev. Benzoxocin and benzoxonin derivatives. Novel groups of terpenophenols with central nervous system activity. A correction. *J. Med. Chem.*, 18, 951-952 (1975).

74. R. Mechoulam, N.K. McCallum, N. Lander, B. Yagen, Z. Ben-Zvi and S. Levy. Aspects of cannabis chemistry and metabolism in "Cannabis Pharmacology", Raven Press, (Eds. M. Braude and S. Szara) pp 39-48 (1976).

75. N. Lander, Z. Ben-Zvi, R. Mechoulam, B. Martin, M. Nordqvist and S. Agurell. Total syntheses of cannabidiol and Δ^1 -THC metabolites. *J. Chem. Soc., Perkin I*, 8-16 (1976).

76. R. Mechoulam, N.K. McCallum and S. Burstein. Recent advances in the chemistry and biochemistry of cannabis. *Chem. Reviews* 76, 75-112 (1976).

77. R. Mechoulam, N. McCallum, S. Levy and N. Lander. Cannabinoid chemistry – an overview. In “Marihuana, Chemistry and Cellular Effects” (Ed. G.G. Nahas) Springer-Verlag, New York, 1976, pp 3-13.

78. N. Lander and R. Mechoulam. Formation of o-methenes by acid catalysed ring opening of α -pinene derivatives. *J. Chem. Soc., Perkin I*, 484-488 (1976).

79. R. Mechoulam, N. Lander, S. Dikstein, E.A. Carlini and M. Blumenthal. On the therapeutic possibilities of some cannabinoids. in “The Therapeutic Potential of Marihuana” (Eds. S. Cohen, R.C. Stillman) Raven Press, pp 35-45 (1976).

80. R. Mechoulam. Towards drugs derived from hashish constituents. *Harafuah*, 90, 378-380 (1976). (In Hebrew).

81. R. Mechoulam. Cannabis. *La Recherche (Paris)* 7, 1018-1026 (1976).

82. A.Y. Meyer, R. Pasternak, J. Sterling, N. Lander and R. Mechoulam. Spectral effects in cyclobutane derivatives. The bathochromic-hypochromic shifts in compounds related to verbenone. *Tetrahedron* 32, 2805-2810 (1976).

83. A. Goldblum and R. Mechoulam. Sodium chromate oxidation of enol benzoates: Allylic oxidation versus a novel rearrangement. *J. Chem. Soc. Perkin I*, 1889-1898 (1977).

84. N.K. McCallum, A. Gugelmann, C.A.M. Brenninkmeijer and R. Mechoulam. Isotope effect studies on the dehydrogenation of the Δ^1 -THC in the rat. *Experientia*, 33, 1012-1013 (1977).

85. B. Yagen, S. Levy, R. Mechoulam and Z. Ben-Zvi. Synthesis and enzymatic formation of a C-glucuronide of Δ^6 -THC. *J. Amer. Chem. Soc.*, 99, 6444-6446 (1977).

86. P.G. Jones, L. Flavello, O. Kennard, G.M. Sheldrick and R. Mechoulam. Cannabidiol. *Acta Cryst.* B33, 3211-3214 (1977).

87. R. Mechoulam and E. Carlini. Toward drugs derived from Cannabis. *Naturwissenschaft*, 65, 174-179 (1978).
88. S. Levy, B. Yagen and R. Mechoulam. Identification of C-glucuronide of Δ^6 -THC in a mouse liver. *Science*, 200, 1391-1392 (1978).
89. M. Bialer, B. Yagen and R. Mechoulam. A total synthesis of distamycin A, an antiviral antibiotic. *Tetrahedron*, 34, 2389-2391 (1979).
90. I. Tamir, D. Lichtenberg and R. Mechoulam. Interaction of cannabinoids with model membranes-NMR studies. in "NMR spectroscopy in molecular biology". (Ed) B. Pullman. D. Reidel Publ., Dordrecht, Holland, pp 405-422 (1978).
91. A. Ohlsson, S. Agurell, K. Leander, J. Dahmen, H. Edery, G. Porath, S. Levy and R. Mechoulam. Synthesis and psychotropic activity of side chain hydroxylated Δ^6 -THC metabolites. *Acta Pharm. Suec.*, 16, 21-33 (1979).
92. S. Agurell, C. Edward, M. Halldin, K. Leander, S. Levy, J.E. Lindgren, R. Mechoulam, M. Nordqvist and A. Ohlsson. Chemical synthesis and biological occurrence of carboxylic acid metabolites of Δ^6 -THC. *Drug Metab. Dispos.*, 7, 155-161 (1979).
93. M. Bialer, B. Yagen, R. Mechoulam and Y. Becker. Structure-activity relationships of pyrroleamidine antiviral antibiotics. 1. Modifications of the alkylamidine side chain. *J. Med. Chem.*, 22, 1296-1301 (1979).
94. R. Mechoulam and N. Lander. Cannabis, a possible source of new drugs. *Pharmacy International*, 1, 19-21 (1979).
95. S. Rosell, U. Bjorkroth, S. Agurell, K. Leander, A. Ohlsson, B. Martin and R. Mechoulam. Relation between effects of cannabinoid derivatives on the twitch response of the isolated guinea-pig ileum and their psychotropic properties. in "Marihuana: Biological Effects" (Eds.) G.G. Nahas and W.D.M. Paton. Pergamon Press, Oxford, 63-7- (1979).

96. I. Tamir, R. Mechoulam and A.Y. Meyer. Cannabidiol and Phenytoin: A structural comparison. *J. Med. Chem.*, 23, 220-223 (1980).

97. J.M. Cunha, E.A. Carlini, A.E. Pereira, O.L. Ramos, G. Pimentel, R. Gagliardi, E.L. Sanvito, N. Lander and R. Mechoulam. Chronic administration of CBD to healthy volunteers and epileptic patients. *Pharmacologia*, 21, 175-185 (1980).

98. T. Cordova, D. Ayalon, N. Lander, R. Mechoulam, I. Nir, M. Puder and H.R. Lindner. The ovulation blocking effect of cannabinoids: structure-activity relationships. *Psychoneuroendocrinology* 5, 53-62 (1980).

99. R. Mechoulam, N. Lander, I. Tamir, Z. Ben-Zvi and Y. Kimmel. Base – catalysed conversion of an equatorial into an axial methoxycarbonyl group due to a 1,5 – long range substituent effect. *Angew. Chem. Int. Ed.*, 19, 543 (1980). German version: 92, 577-578 (1980).

100. R. Mechoulam, N. Lander, T.H. Varkony, I. Kimmel, O. Becker, Z. Ben-Zvi, H. Edery and G. Porath. Stereochemical requirements for cannabinoid activity. *J. Med. Chem.*, 23, 1068-1072 (1980).

101. M. Bialer, B. Yagen, R. Mechoulam and Y. Becker. Structure activity relationships of pyrrole amidine antiviral antibiotics. 2. Preparation of mono and tri-pyrrole derivatives of congocidine. *J. Med. Chem.*, 23, 1144-1148 (1980).

102. A.V. Revuelta, D.L. Cheney, E. Costa, N. Lander and R. Mechoulam. Reduction of hippocampal acetylcholine turnover in rats treated with (-) Δ^8 -THC and its 1,2-dimethylheptyl homolog. *Brain Research*, 195, 445-452 (1980).

103. M. Bialer, B. Yagen, R. Mechoulam and Y. Becker. Structure activity relationships of pyrrole amidine antiviral antibiotics. 3. Preparation of distamycin and congocidine derivatives based on 2,5-disubstituted pyrroles. *J. Pharm. Sci.*, 69, 1334-1338 (1980).

104. M. Bialer, B. Yagen and R. Mechoulam. Structure elucidation of a condensation product of 4-aminopyrrole derivatives and dicyclohexylcarbodiimide. *J. Heterocyclic Chem.*, 17, 1797-1798 (1980).

105. T.U.C. Jarbe, M.D.B. Swedberg and R. Mechoulam. A repeated tests procedure to assess onset and duration of the cue properties of $(-)\Delta^9$ -THC, $(-)\Delta^8$ -THC-DMH and $(+)\Delta^8$ -THC. *Psychopharmacol.*, 75, 152-157 (1981).
106. M. Noam, I. Tamir, E. Breuer and R. Mechoulam. Conversion of ruscogenin into 1α and 1β -hydroxy-cholesterol derivatives; structure elucidation by computer assisted analysis of their lanthanide – induced nmr shifts. *Tetrahedron*, 37, 597-604 (1981).
107. R. Mechoulam. Current status of therapeutic opportunities based on cannabinoid research. An overview. *Clin. Pharmacol. Ther.*, 21S, 2-7, (1981).
108. U. Zehavi and R. Mechoulam. O- and C-, D-glucosyluronic acid derivatives of Δ^1 -THC: synthesis and differential behaviour of β -glucuronidase. *Carbohydr. Res.* 98, 143-147 (1981).
109. M. Bialer, J. El-On, B. Yagen and R. Mechoulam. Antiparasitic structure-activity relationships of congocidine derivatives. *J. Pharm. Sci.*, 70, 822-824 (1981).
110. R. Mechoulam. Chemistry of Cannabis. Handbook of Experimental Pharmacology Volume “Psychotropic Agents”. Part 2. Springer-Verlag, Berlin – Heidelberg, New York, pp 119-134 (1982).
111. J.R. Leite, E.A. Carlini, N. Lander and R. Mechoulam. Anticonvulsant effect of $(-)$ and $(+)$ isomers of CBD and their dimethyl heptyl homologs. *Pharmacol.*, 124, 141-146 (1982).
112. P. Consroe, M.A.C. Benedito, J.R. Leite, E.A. Carlini and R. Mechoulam. Effect of CBD on behavior seizures caused by convulsant drugs or current in mice. *Eur. J. Pharmacol.*, 83, 293-298 (1982).
113. M. Bialer, B. Yagen, R. Mechoulam, Y. Becker and J. El-On. Antiparasitic and antiviral SAR of Congocidine and Distamycin. A derivatives. Current Chemotherapy and Immunotherapy. Proceedings 12th Intern. Congr. Chemother., vol. 11, pp 1048-1050 (1982).

114. R. Mechoulam, N. Lander, M. Srebnik, I. Zamir, A. Breuer, B. Shalita, S. Dikstein, E.A. Carlini, J. Roberto Leite, H. Edery and G. Porath. Cannabidiol and THC as starting points in the search for new therapeutic agents. *Actualités de Chimie Thérapeutique*, 10, 214-226 (1983). Same publication also in "The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects," (Eds) S. Agurell, W.L. Dewey, R.S. Willette, Academic Press, pp 777-793 (1984).

115. M. Srebnik and R. Mechoulam. A facile method for regiospecific hydroxylation of resorcinol diethers. *Synthesis*, 1046-1048 (1983).

116. A. Gez, S. Biran, Z. Fuchs, E. Edelstein, N. Lander and R. Mechoulam. Δ^9 -THC for prevention of vomiting and nausea caused by chemical and radiation treatment. *Harefuah*, 55, 306-308 (1983 (in Hebrew)).

117. R. Mechoulam. Research on Cannabis. An overview. *Impact of Science on Society* (A U.N. publication), 34, 23-33 (1984).

118. M. Srebnik and R. Mechoulam. Reactions of cannabinoid tosylhydrazones: stereochemical aspects. *Tetrahedron*, 40, 3839-3843 (1984).

119. H. Edery, G. Porath, R. Mechoulam, N. Lander, M. Srebnik and N. Lewis. Acitivity of novel aminocannabinoids in baboons. *J. Med. Chem.*, 27, 1370-1373 (1984).

120. M. Srebnik and R. Mechoulam. A new facile method for the synthesis of cyclic haloethers and holalactones. *Chem. Commun.* 1070-1071 (1984).

121. M. Srebnik, N. Lander, A. Breuer and R. Mechoulam. Base catalyzed double bond isomerizations of cannabinoids: Structural and stereochemical aspects. *J. Chem. Soc., Perkin Trans I*, 2881-2886 (1984).

122. R. Mechoulam, R.E. Brueggemeier and D.L. Denlinger. Estrogens in insects. *Experientia*, 40, 942-944 (1984).

123. S.H. Baek, M. Srebnik and R. Mechoulam. Borontrifluoride on alumina – a modified Lewis acid reagent. An improved synthesis of cannabidiol. *Tetrahedron Letters*, 26, 1083-1086 (1985).

124. R. Mechoulam, M. Srebnik and S. Burstein. Cannabis Chemistry, Biochemistry and Therapeutic Applications – An Overview. “Marihuna '84. Proceedings of the Oxford Symposium on Cannabis”, (Ed) D.J. Harvey, IRL Press Ltd., Oxford, pp 1-12 (1985).

125. P. Consroe, A. Martin and R. Mechoulam. Anticonvulsant effects of cannabidiol stereoisomers and analogs in rats. *Ibid.*, pp 705-712 (1985).

126. R.E. Musty, L.H. Conti and R. Mechoulam. Anxiolytic properties of cannabidiol. *Ibid.*, pp 713-719 (1985).

127. R. Mechoulam (Ed); Cannabinoids as Therapeutic Agents. (A Monograph); author of Chapter 1: The Pharmacohistory of Cannabis sativa. CRC Press Inc., Boca Raton, Fla., pp 1-19 (1986).

128. 128 .T.U.C. Jarbe, A.J. Hiltunen, N. Lander and R. Mechoulam. Cannabimimetic activity (Δ^1 -THC cue) of cannabidiol momethyl ether and two stereoisomeric hexahydrocannabinols in rats and pigeons. *Pharmacol. Biochem. & Behav.*, 25, 393-399 (1986).

129. S. Burstein, S.A. Hunter, V. Latham, R. Mechoulam, D.L. Melchior, L. Renzulli and R.E. Tefft, Jr. Prostaglandins and Cannabid XV. Comparison of enantiomeric cannabinoids in stimulating prostaglandin synthesis in fibroblasts. *Life Sci.*, 39, 1813-1923 (1986).

130. D.L. Denlingr, R.W. Brueggemeir, R. Mechoulam, N. Katlic, L.B. Yocum and G.D. Yocum. Estrogens and androgens in insects. in: “Molecular Entomology”. (Ed) J. Law. Alan R. Liss, N.Y. pp 189-199 (1987).

131. R. Mechoulam, N. Lander, M. Srebnik, A. Breuer, M. Segal, J.J. Feigenbaum, T.U.C. Jarbe and P. Consroe. Stereochemical requirements for cannabimimetic activity. in: “Structure Activity Relationships of the Cannabinoids”. (Eds) R.S. Rapaka and A. Makriyannis. National Institute on Drug Abuse. Monograph 79 Washington DC pp. 15-30 (1987).

132. P. Consroe and R. Mechoulam. Anticonvulsant and neurotoxic effects of tetrahydrocannabinol stereoisomers. in: “Structure Activity Relationships of the Cannabinoids”. (Eds) R.S. Rapaka and

A. Makriyannis. National Institute on Drug Abuse. Monograph 79 Washington DC pp. 59-66 (1987).

133. P. Consroe, V.V. Kane, A.R. Martin, V. Shah, V. Singh, N. Lander, R. Mechoulam and M. Srebnik. Structure-anticonvulsant activity relationships of cannabidiol analogs. in: "Structure Activity Relationships of the Cannabinoids". (Eds) R.S. Rapaka and A. Makriyannis. National Institute on Drug Abuse. Monograph 79 Washington DC pp. 48-58 (1987).

134. R. Mechoulam and J.J. Feigenbaum. Towards cannabimimetic drugs. in: "Progr. Med. Chem." (Eds) G.P. Ellis and G.B. West. Vol. 24, pp. 159-207 (1987).

135. L.B. Yocom, D.L. Denlinger, N.E. Katlic, R.W. Brueggemeir and R. Mechoulam. A developmental profile of estrogen and androgen radioimmunoactive substances in the flesh fly, Sarcophaga crassicalpis. Insect Biochemistry 17, 1149-1153 (1987).

136. M. Srebnik, R. Mechoulam and I. Iona. Halogenation of phenols and phenol ethers with potassium halides in 18-crown-6 on oxidation with m-chloroperbenzoic acid. J. Chem. Soc. Perkin Trans. I. 1423-1427 (1987).

137. L.E. Hollister, H.K. Gillespie, R. Mechoulam and M. Srebnik. Human pharmacology of 1S and 1R enantiomers of delta-3-THC. Psychopharmacology 92, 505-507 (1987).

138. T.U.C. Jarbe, A.J. Hiltunen, R. Mechoulam, M. Srebnik and A. Breuer. Separation of the discriminative stimulus effects in stereoisomers of delta-2- and delta-3 tetrahydrocannabinols in pigeons. Eur. J. Pharmacol. 156, 361-366 (1988).

139. E. Samara, M. Bialer and R. Mechoulam. Pharmacokinetics of cannabidiol in dogs. Drug Metab. Disposition 16, 469-472 (1988).

140. R. Mechoulam, J.J. Feigenbaum, N. Lander, M. Segal, T.U.C. Jarbe, A.J. Hiltunen and P. Consroe. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 44, 762-764 (1988).

141. R. Mechoulam, J.J. Feigenbaum, N. Lander, A. Breuer, P. Consroe, T.U.C. Jarbe and A.J. Hiltunen. Stereospecificity and

stereoselectivity of cannabinoid action, in "Marijuana: An International Research Report" (eds. G. Chesher, P. Consroe and R. Musty) Australian Government Publishing Service, Canberra 1988, 243-251.

142. A.R. Martin, V. Shah, P. Consroe, S.H. Baek, R. Mechoulam and M. Srebnik. Anticonvulsant cannabidiol analogs modified in the terpene ring *ibid*, pp 163-166.

143. R. Mechoulam. Alkaloids in *Cannabis sativa L.* in "The Alkaloids" vol. 34 (Ed. A. Brossi), Academic Press, San Diego, pp. 77-93 (1988).

144. R. Mechoulam, J.J. Feigenbaum, A. Breuer, J. Zahalka, N. Lander, T.U.C. Jarbe, A.J. Hiltunen and R. Glaser. Cannabinoids: Differential stereochemical requirements for cannabimimetic and therapeutic activity, in: "Trends in Med. Chem. '88." (Eds. H. van der Goot, D. Domany, L. Pallos and H. Timmerman). Pp. 467-481 (1989).

145. T.U.C. Jarbe, A.J. Hiltunen and R. Mechoulam. Subjectively experienced Cannabis effects in animals. *Drug Dev. Res.* 16, 385-394 (1989).

146. P.J. Little, D.R. Compton, R. Mechoulam and B. Martin. Stereochemical effects of 11-OH-delta-8-THC-dimethylheptyl in mice and dogs. *Pharmacol. Biochem. Behavior* 32, 661-666 (1989).

147. T.U.C. Jarbe, A.J. Hiltunen and R. Mechoulam. Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-OH-delta-8-tetrahydrocannabinol in rats and pigeons. *J. Pharmacol. Exper. Ther.* 250, 1000-1005 (1989).

148. J.J. Feigenbaum, S.A. Richmond, Y. Weissman and R. Mechoulam. Inhibition of cisplatin induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid. *Eur. J. Pharmacol.* 169, 159-165 (1989).

149. J.J. Feigenbaum, F. Bergmann, S.A. Richmond, R. Mechoulam, V. Nadler, Y. Kloog and M. Sokolovsky. A non-psychotropic cannabinoid acts as a functional N-methyl-D-aspartate (NMDA) receptor blocker. *Proc. Nat. Acad. Sci.* 86, 9584-9587 (1989).

150. N. Titishov, R. Mechoulam, A.M. Zimmerman. Stereospecific effects of (-) and (+)-7-hydroxy-delta-6-tetrahydrocannabinol-dimethyl-heptyl on the immune system of mice. *Pharmacology* 39, 337-349 (1989).

151. A.C. Howlett, T.M. Champion, G.H. Wilken and R. Mechoulam. Stereochemical effects of 11-OH-delta-8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. *Neuropharmacol.* 29, 161-165 (1990).

152. R. Mechoulam, A. Breuer, T.U.C. Jarbe, A.J. Hiltunen and R. Glaser. Cannabimimetic activity of novel enantiomeric benzofuran cannabinoids. *J. Med. Chem.* 33, 1037-43 (1990).

153. D.J. Harvey and R. Mechoulam. Metabolites of cannabidiol identified in human urine. *Xenobiotica*, 20, 303-320 (1990).

154. R. Mechoulam, N. Lander, A. Breuer and J. Zahalka. Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative. *Tetrahedron: Asymmetry*, 1, 315-319 (1990).

155. D.J. Harvey, E. Samara and R. Mechoulam. Urinary metabolites of cannabidiol in dog, rat and man and their identification by gas chromatography mass spectrometry. *J. Chromatogr. Biomed. Appl.*, 562, 299-322 (1991).

156. R. Mechoulam, A. Breuer, J.J. Feigenbaum, W.A. Devane. Nonpsychotropic synthetic cannabinoids as therapeutic agents. *Farmaco*, 46, 267-276 (1991).

157. R. Seltzer, Z. Zeltser, A. Eisen, J.J. Feigenbaum and R. Mechoulam. Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor- blocking properties. *Pain* 47, 95-103 (1991).

158. R. Mechoulam, W.A. Devane, A. Breuer and J. Zahalka. A random walk through a Cannabis Field. *Pharmacol. Biochem. Behavior* 40, 461-464 (1991).

159. B.R. Martin, D.R. Compton, B.F. Thomas, W.R. Prescott, P.J. Little, R.K. Razdan, M.R. Johnson, L.S. Melvin, R. Mechoulam and S.J. Ward. Behavioral, biochemical and molecular modeling evaluations

of cannabinoid analogs. *Pharmacol. Biochem. Behavior* 40, 471-478 (1991).

160. D.J. Harvey, E. Samara and R. Mechoulam. Comparative metabolism of cannabidiol in dog, rat and man. *Pharmacol. Biochem. Behavior* 40, 523-532 (1991).

161. A.M. Zimmerman, N. Titishov, R. Mechoulam and S. Zimmerman. Effect of stereospecific cannabinoids on the immune system, in "Drugs of Abuse, Immunity and Immunodeficiency", H. Friedman et al. ed. Plenum Press, New York, 1991, pp. 71-80.

162. W.A. Devane, A. Breuer, T. Sheskin, T.U.C. Jarbe, M. Eisen and R. Mechoulam. A novel probe for the cannabinoid receptor. *J. Med. Chem.* 35, 2065-2069 (1992).

163. R.G. Pertwee, L.A. Stevenson, D.B. Elrick, R. Mechoulam and A.D. Corbett. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. *Brit. J. Pharmacol.* 105, 980-984 (1992).

164. R. Mechoulam, W.A. Devane and R. Glaser. Cannabinoid geometry and biological activity, in "Marijuana/cannabinoids: neurobiology and neurophysiology" ed. L. Murphy and A. Bartke, CRC Press, Boca Raton, FL., 1992, 1-33. Reprinted in "Marijuana and Medicine" (eds. G.G. Nahas, K.M. Sutin, D. Harvey and S. Agurell) Humana Press, Totowa, N.J., 1999, pp. 65-90.

165. S.H. Burstein, C.A. Audette, A. Breuer, W.A. Devane, S. Colodner, S.A. Doyle and R. Mechoulam. Synthetic non-psychotropic cannabinoids with potent antiinflammatory, analgesic and leukocyte antiadhesion activities. *J. Med. Chem.* 35, 3135- 3141 (1992).

166. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Ettinger and R. Mechoulam. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258, 1946-1949 (1992).

167. I. Nathan, G. Agam, R. Mechoulam, A. Dvilansky, A.A. Livne. Effect of synthetic enantiomeric cannabinoids on platelet aggregation. *Canadian J. Physiol. and Pharmacol.* 70, 1305-1308 (1992).

168. E. Fride and R. Mechoulam. Pharmacological activity of the cannabinoid agonist anandamide, a brain constituent. *Eur. J. Pharmacol.* 231, 313-314 (1993).

169. T.U.C. Jarbe, A.J. Hiltunen, D.A. Mathis, L. Hanus, A. Breuer and R. Mechoulam. Discriminative stimulus effects and receptor binding of enantiomeric pairs of cannabinoids in rats and pigeons: a comparison. *J. Pharmacol. Exp. Ther.* 264, 561-569 (1993).

170. Z. Vogel, J. Barg, R. Levy, D. Saya, E. Heldman and R. Mechoulam. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. *J. Neurochem.* 61, 352-355 (1993).

171. J. Zias, H. Stark, J. Seligman, R. Levy, E. Werker, A. Breuer and R. Mechoulam. Early medical use of Cannabis. *Nature* 363, 215 (1993).

172. B.R. Martin, G. Cabral, S.R. Childers, S. Deadwyler, R. Mechoulam and P. Reggio. International Cannabis Research Society Meeting Summary, Keystone, CO. (June 19-20, 1992). *Drug and Alcohol Dependence* 31, 219-227 (1993).

173. V. Nadler, R. Mechoulam and M. Sokolovsky. Blockage of $^{45}\text{Ca}^{2+}$ influx through the N-methyl-D-aspartate receptor ion channel by the nonpsychoactive cannabinoid HU-211. *Brain Res.*, 622, 79-85 (1993).

174. E. Shohami, M. Novikov and R. Mechoulam. A non-psychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. *J. Neurotrauma*, 10, 109-119 (1993).

175. L. Hanus, A. Gopher, S. Almog and R. Mechoulam. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. *J. Med. Chem.* 36, 3032-3034 (1993).

176. V. Nadler, R. Mechoulam and M. Sokolovsky. The nonpsychoactive cannabinoid (+)-(3S,4S)-7-Hydroxy-delta-6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate-receptor-mediated neurotoxicity in primary cultures of rat forebrain. *Neurosci. Lett.* 162, 43-45 (1993).

177. S. Levin, S. Abu-Lafi, J. Zahalka and R. Mechoulam. Resolution of chiral cannabinoids on amylose tris(3,5-dimethylphenylcarbamate) chiral stationary phase: effects of structural features and mobile phase additives. *J. Chromat. A.*, 654, 53-64, (1993).

178. T.U.C. Jarbe, R. Mechoulam and J.Zahalka. Discriminative stimulus- and open-field effect of the enantiomers of 11-hydroxy-delta-8-tetrahydrocannabinol in pigeons and gerbils. *Pharmacol. Biochem. Behav.* 47, 113-119 (1994)

179. S. Abu-Lafi, M. Sterin, S. Levin and R. Mechoulam. Structural features affecting chiral discrimination of terpene derivatives on a carbamated amylose stationary phase. *J. Chromatog. A.* 664, 159-167 (1994).

180. J. Weidenfeld, S. Feldman and R. Mechoulam. The effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. *Neuroendocrinology* 59, 110-112 (1994).

181. F. S. Guimaraes, J.C. de Aquiar, R. Mechoulam and A. Breuer. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. *General Pharmacology* 25, 161-164 (1994).

182. F.R. de Fonseca, J.L.M. Calderon, R. Mechoulam and M. Navarro. Repeated stimulation of D₁ dopamine receptors enhances (-)-11-hydroxy-delta-8-tetrahydrocannabinol-dimethylheptyl in induced catalepsy in male rats. *Neuro-report* 5, 761-765 (1994).

183. R. Mechoulam, L. Hanus and B.R. Martin. The search for endogenous ligands of the cannabinoid receptor. Commentary. *Biochem. Pharmacol.* 48, 1537-1544 (1994).

184. P.B. Smith, D.R. Compton, S.P. Welch, R.K. Razdan, R. Mechoulam and B.R. Martin. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. *J. Pharmacol. Exp. Ther.* 270, 219-227 (1994).

185. R.G. Pertwee, G. Griffin, L. Hanus and R. Mechoulam. Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. *Eur. J. Pharmacol.* 259, 115-120 (1994).

186. H. Schuel, E. Goldstein, R. Mechoulam, A.M. Zimmerman and S. Zimmerman. Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. *Proc. Natl. Acad. Sci.* 91, 7678-7682 (1994).

187. R. Mechoulam. Cannabis chemistry, biochemistry, toxicology and therapeutic applications. *Jap. J. Foren. Toxicol.* 12, 76-83 (1994).

188. R. Mechoulam, Z. Vogel and J. Barg. CNS Cannabinoid receptors: Role and therapeutic implications for CNS disorders. *CNS Drugs*, 2, 255-260 (1994).

189. I. Wirguin, R. Mechoulam, A. Breuer, E. Schezen, J. Weidenfeld and T. Brenner. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. *Immunopharm.* 28, 209-214 (1994).

190. Z. Vogel, M. Bayewitch, R. Levy, N. Matus-Leibovitch, L. Hanus, S. Ben-Shabat, R. Mechoulam, T. Avidor-Reiss and J. Barg. Binding and functional studies with the peripheral and neuronal cannabinoid receptors. *Regulat. Pept.* 54, 313-314 (1994).

191. E. Fride, L. Hanus and R. Mechoulam. Discovery of the anandamides, a family of endogenous ligands for the cannabinoid receptor in the brain. In "Lipid mediators in health and disease (LMHD). (ed. U. Zor), Freund Publ. London, 1-10 (1994).

192. R. Mechoulam and E. Fride. The unpaved road to the endogenous brain cannabinoid ligands, the anandamides in "Cannabinoid Receptors" (ed. R. Pertwee), Academic Press, London. Pp. 233-258 (1995).

193. R. Glaser, I. Adin, R. Mechoulam and L. Hanus. 2-Methyl and 4-methyl-delta-8-tetrahydrocannabinol: correlation of spatial distinction with cannabinoid receptor binding. *Heterocycles* 39, 867-877 (1995).

194. H. Ovadia, A. Wohlman, R. Mechoulam and J. Weidenfeld. Characterization of the hypothermic effect of the synthetic

cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. *Neuropharmacology* 34, 175-180 (1995).

195. E. Fride, J. Barg, R. Levy, D. Saya, R. Heldman, R. Mechoulam and Z. Vogel. Low doses of anandamides inhibit pharmacological effects of delta-9-tetrahydrocannabinol. *J. Pharmacol. Exp. Ther.* 272, 699-707 (1995).

196. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, A.R. Schatz, A. Gopher, S. Almog, B.R. Martin, D.R. Compton, R.G. Pertwee, G. Griffin, M. Bayewitch, J. Barg and Z. Vogel. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem. Pharmacol.* 50, 83-90 (1995).

197. A. Abrahamov, A. Abrahamov and R. Mechoulam. An efficient new cannabinoid antiemetic in pediatric oncology. *Life Sciences* 56, 2097-2102 (1995).

198. R. Mechoulam. The biochemical basis of Cannabis activity. *Atti e Relazioni (Accademia Pugliese della Scienze)* XLVII, Tomo II, 25-26 (1990).

199. R. Mechoulam. Hashish (a semipopular review in Hebrew) in "Drugs: Facts, Questions and Problems" (D. Green, ed.), Ministry of Education, p 66-74 (1995).

200. F. Taura, S. Morimoto, Y. Shoyama and R. Mechoulam. First direct evidence for the mechanism of Δ^1 -tetrahydrocannabinolic acid biosynthesis. *J. Amer. Chem. Soc.* 117, 9766-9767 (1995).

201. A.W. Zuardi, S.L. Morais, F.S. Guimaraes and R. Mechoulam. Antipsychotic effect of cannabidiol. *J. Clin. Psychiatry* 56, 485-486 (1995).

202. M. Bayewitch, T. Avidor-Reiss, R. Levy, J. Barg, R. Mechoulam and Z. Vogel. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. *FEBS Letters* 375, 143-147 (1995).

203. J. Barg, E. Fride, L. Hanus, R. Levy, N. Matus-Leibovitch, E. Heldman, M. Bayewitch, R. Mechoulam and Z. Vogel.

Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. *Eur. J. Pharmacol.* 287, 145-152 (1995).

204. E. Fride and R. Mechoulam. Developmental aspects of anandamide: Ontogeny of response and effects of prenatal exposure to anandamide. *Psychoneuroendocrinology* 21, 157-172 (1996).

205. E. Pop, Z.Z. Liu, M.E. Brewster, Y. Barenholz, V. Korablyov, R. Mechoulam, V. Nadler and A. Beigon. Derivatives of dexanabinol. I. Water-soluble salts of glycinate esters. *Pharmac. Res.* 13, 62-69 (1996).

206. M. Bayewitch, M.-H. Rhee, T. Avidor-Reiss, A. Breuer, R. Mechoulam and Z. Vogel. (-)- Δ^9 -Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. *J. Biol. Chem.* 271, 9902-9905 (1996).

207. E. Pop, F. Soti, M.E. Brewster, Y. Barenholz, V. Korablyov, R. Mechoulam, V. Nader and A. Beigon. Derivatives of dexanabinol. II. Salts of amino acid esters containing tertiary and quaternary heterocyclic nitrogen with increased water solubility. *Pharmac. Res.* 13, 469-475 (1996).

208. E. Fride and R. Mechoulam. Ontogenetic development of the response to anandamide and Δ^9 -tetrahydrocannabinol in mice. *Dev. Brain Res.* 95, 131-134 (1996).

209. R.G. Wilson, S.K. Tahir, R. Mechoulam, S. Zimmerman, A.M. Zimmerman. Cannabinoid enantiomer action on the cytoarchitecture. *Cell Biol. Intnl.* 20, 147-157 (1996).

210. R. Mechoulam, S. Ben Shabat, L. Hanus, E. Fride, M. Bayewitch and Z. Vogel. "Endogenous Cannabinoid Ligands" Advances in Experimental Biology and Medicine, 402, 95-101, 1996: "AIDS, Drugs of Abuse, and the Neuroimmune Axis" (Ed. Friedman et al.) Plenum Press, New York.

211. R. Mechoulam, S. Ben Shabat, L. Hanus, E. Fride, Z. Vogel, M. Bayewitch, A.E. Sulcova. Endogenous cannabinoid ligands –

Chemical and biological studeis. *J. Lipid Mediat. and Cell Signall.* 14, 45-49 (1996).

212. R. Mechoulam. Endogenous cannabinoid ligands. *J. Neuroimmunology* 69, 17-18 (1996).

213. E. Shohami, J. Weidenfeld, H. Ovadia, Z. Vogel, L. Hanus, E. Fride, A. Breuer, S. Ben-Shabat, T. Sheskin and R. Mechoulam. Endogenous and synthetic cannabinoids: recent advances. *CNS Drug Reviews* 2, 429-451 (1996).

214. T. Sheskin, L. Hanus, J. Slager, Z. Vogel, R. Mechoulam. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. *J. Med. Chem.* 40, 659-667 (1997).

215. E. Shohami, R. Gallily, R. Mechoulam, R. Bass, and T. Ben-Hur. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel $\text{TNF}\alpha$ inhibitor and an effective neuroprotectant. *J. Neuroimmunol.* 72, 169-177 (1997).

216. R. Mechoulam, Todd's achievement. *Nature* (letter to the Editor). 386, 755 (1997).

217. R. Mechoulam, E. Fride, L. Hanus, T. Sheskin, T. Bisogno, V. Di Marzo, M. Bayewitch and Z. Vogel. Anandamide may mediate sleep induction. *Nature* 389, 25-26 (1997).

218. M.-H. Rhee, Z. Vogel, J. Barg, M. Bayewich, R. Levy, L. Hanus, A. Breuer and R. Mechoulam. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylyl cyclase. *J. Med. Chem.* 40, 3228-3233 (1997).

219. R. Gallily, A. Yamin, Y. Waksmann, H. Ovadia, J. Weidenfeld, A. Bar-Joseph, A. Biegon, R. Mechoulam and E. Shohami. Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. *J. Pharmacol. Exp. Ther.* 283, 918-924 (1997).

220. T. Bisogno, N. Sepe, L. DePetrocellis, R. Mechoulam and V. Di Marzo. The sleep inducing factor oleamide is produced by

mouse neuroblastoma cells. *Biochem. Biophys. Res. Comm.* 239, 473-353 (1997).

221. E. Sulcova, R. Mechoulam and E. Fride. Biphasic effects of anandamide. *Pharmacology, Biochemistry and Behavior* 59, 347- 353 (1998).
222. R. Mechoulam, L. Hanus and E. Fride. Towards cannabinoid drugs – revisited. A review chapter in *Progress in Medicinal Chemistry*, ed. G.P. Ellis, 35, 199-243 (1998).
223. S. Ben-Shabat, E. Fride, T. Sheskin, T. Tamiri, M.-H. Rhee, Z. Vogel, T. Bisogno, L. De Petrocellis, V. Di Marzo and R. Mechoulam. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. *Eur. J. Pharmacol.* 353, 23-31 (1998).
224. R. Mechoulam and D. Golan. A comment on ‘Health aspects of cannabis: revisited’ (Hollister). *Intl. J. Neuro-Psychol. Pharmacol.* 1, 83-85 1998).
225. R. Mechoulam, E. Fride and V. Di Marzo. Endocannabinoids. *Eur. J. Pharmacol.* 359, 1-18 (1998).
226. V. Di Marzo, N. Sepe, L. De Petrocellis, A. Berger, G. Crozier, E. Fride and R. Mechoulam. Trick or treat from food endocannabinoids? *Nature* 396, 636-637 (1998).
227. R. Mechoulam, E. Fride, S. Ben-Shabat, U. Meiri and M. Horowitz. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. *Eur. J. Pharmacol.* 362, R1-R3 (1998).
228. R. Mechoulam, Published plenary and invited lectures:
 - a. The ongoing story of Cannabis sativa: from Cannabis resin to cannabinoids, anandamide and 2-arachidonoyl glycerol. Kyoto, 1997, “Towards Natural Medicine Research in the 21st Century”, H. Ageta et al., eds, Elsevier, 1998 pp. 457-466.
 - b. R. Mechoulam, The endogenous vertebrate cannabinoids, Oslo, 1998, “The Fifth Nordic Seminar on Drugs of Abuse Testing, pp. 5-10; Cannabinoids as medicinal agents, ibid., pp. 15-18.

229. a. R. Mechoulam and S. Ben-Shabat. From Gan-Zi-Gun-Nu to anandamide and 2-arachidonoyl-glycerol, the ongoing story of Cannabis. *Natural Products Reports* 16, 131-143 (1999). b. A modified short version has been published: R. Mechoulam. From Gan-Zi-Gun-Nu to anandamide – the ongoing story. *ICRS Newsletter of the International Cannabinoid Research Society*, Spring 1998, vol. 8, No. 1 (1998).

230. B.R. Martin, R. Mechoulam and R.K. Razdan. Discovery and characterization of endogenous cannabinoids. *Life Sci.* 65, 573-595 (1999).

231. R. Mechoulam. Recent advances in cannabinoid research. *Fortschende Komplementarmedicine*, 6, 16-20 (1999).

232. L. Hanus, A. Breuer, S. Tchilibon, S. Shiloah, D. Goldenberg, M. Horowitz, R.G.Pertwee , R.A.Ross, R. Mechoulam and E. Fride. HU-308: A specific agonist for CB₂, a peripheral cannabinoid receptor. *Proc. Natl. Acad. Sci. (US)*, 96, 14228-14233 (1999).

233. I. Ginsburg, M. Sadovnik, S. Sallon, I. Milo-Goldzweig, R. Mechoulam, A. Breuer, D. Gibbs, J. Varani, S. Roberts, E. Cleator and N. Singh. PADMA-28, a traditional Tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids. *Inflammopharmacol.* 7, 47-62 (1999).

234. S. Hao, Y. Avraham, R. Mechoulam and E.M. Berry. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. *Eur. J. Pharmacol.* 392, 147-156 (2000).

235. N. Naveh, C. Weissman, S. Muchtar, S. Benita and R. Mechoulam. A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. *Graefes Arch. Clin. Exper. Ophthal.* 238, 334-338 (2000).

236. R. Mechoulam. Looking back at Cannabis research. *Curr. Pharmac. Des.* 6, 1313-1322 (2000).

237. E. Shohami and R. Mechoulam. Dexanabinol (HU-211): A nonpsychotropic cannabinoid with neuroprotective properties. *Drug Dev. Res.* 50, 211-215 (2000).

238. R. Mechoulam. A Cannabis tale. History, chemistry and biology of marijuana. *Sci. Spectra* 21, 44-51 (2000). (Semi-popular)

239. R. Mechoulam and L. Hanus. A historical overview of chemical research on cannabinoids. *Chem. Phys. Lipids* 108, 1-13 (2000).

240. A.M. Malfait, R. Gallily, P.F. Sumariwalla, A.S. Malik, E. Andreakos, R. Mechoulam, M. Feldmann. The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritis therapeutic in murine collagen-induced arthritis. *Proc. Natl. Acad. Sci (USA)* 97, 9561-9566 (2000).

241. R. Gallily, A. Breuer and R. Mechoulam. 2-Arachidonylglycerol an endogenous cannabinoid, inhibits TNF- α production in murine macrophages, and in mice. *Eur. J. Pharmacol.* 406, R5-R7, (2000).

242. Y. Chen, R.M. McCarron, Y. Ohara, J. Bembry, N. Azzam, F.A. Lenz, E. Shohami, R. Mechoulam and M. Spatz. Human brain capillary endothelium 2-arachidonylglycerol (endocannabinoid) interacts with endothelin-1. *Circ. Res.* 87, 323-327 (2000).

243. R. Mechoulam. Blowing away the smokescreen. Book review of “The Science of Marijuana” by Leslie L. Iversen, Oxford. Univ. Press. *Nature* 407, 18-19 (2000).

244. S. Tchilibon and R. Mechoulam. Synthesis of a primary metabolite of cannabidiol. *Org. Letters* 2, 3301-3303(2000).

245. R. Mechoulam. The chemistry and biological effects of hashish. A review (in Hebrew). *Chemistry in Israel – Bulletin of the Israel Chemical Society* 5, 4-7 (2000).

246. R. Mechoulam. Exogenous and endogenous cannabinoids: understanding of psychotropic properties and medicinal aspects. *Suchtmed* 2, 209-212 (2000).

247. D.S. Ugdyzhekova, Y.G. Davydova, L.A. Maimeskulova and R. Mechoulam. Involvement of central and peripheral cannabinoid

receptors in the regulation of heart resistance to arrhythmogenic effects of epinephrine. *Bull. Exp. Biol. & Med.* 130, 1087-1089, (2000).

248. R. Mechoulam and E. Shohami. HU-211, ein neuroprotektives Cannabinoid. In: "Cannabis und Cannabinoide. Pharmacologie, Toxikologie und Therapeutisches Potential". (ed. F. Grotenhermen), Verlag Hans Huber, pp. 415-425 (2001). English Edition: HU-211: A Cannabinoid Neuroprotective Agent: (Eds. F. Grotenhermen and E. Russo) Hawthorn Press Inc. Binghampton, NY, pp. 389-398, (2002).

249. E. Fride, Y. Ginzburg, A. Breuer, T. Bisogno, V. Di Marzo and R. Mechoulam. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. *Eur. J. Pharmacol.* 419, 207-214 (2001).

250. L. Hanus, S. Abu-Lafi, E. Fride, A. Breuer, Z. Vogel, D.E. Shalev, I. Kustanovich and R. Mechoulam. 2-Arachidonyl glycerol ether, endogenous agonist of the cannabinoid CB₁ receptor. *Proceed. Natl. Acad. Sci. (USA)* 98, 3662-3665 (2001).

251. R. Mechoulam and E. Fride. A hunger for cannabinoids. *Nature (News & Views item)* 410, 763-765 (2001).

252. R. Mechoulam and L. Hanus. The cannabinoids: An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. *Pain Res. Manage.* 6, 67-73 (2001).

253. S. Rubnov, Y. Kashman, R. Rabinowitz, M. Schlesinger and R. Mechoulam. Suppressors of cancer cell proliferation from fig (*Ficus carica*) resin: Isolation and structure elucidation. *J. Nat. Prods.* 64, 993-996 (2001).

254. G. Crozier Willi, A. Berger, V. Di Marzo, T. Bisogno, L. De Petrocellis, E. Fride and R. Mechoulam. Lipids in neuronal function: modulation of behavior by oral administration of endocannabinoids found in foods. *Nutr. & Brain.* 5, 169-187 (2001).

255. D. Panikashvili, C. Simeonidou, S. Ben-Shabat, L. Hanus, A. Breuer, R. Mechoulam and E. Shohami. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. *Nature*

413, 527-531 (2001).

256. T. Bisogno, L. Hanus, L. De Petrocellis, S. Tchilibon, D. Ponde, I. Brandi, A.S. Moriello, J.B. Davis, R. Mechoulam and V. Di Marzo. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Brit. J. Pharmacol.* 134, 845-852 (2001).
257. D.S. Ugdyzhekova, N.A. Bernatskaya, J.B. Stefano, V.F. Graier, S.W. Tam and R. Mechoulam. Endogenous cannabinoid anandamide increases heart resistance to arrhythmogenic effects of epinephrine: role of CB₁ and CB₂ receptors. *Bul. Exp. Biol. Med.* 131, 251-253, 2001.
258. A.V. Krylatov, D.S. Ugdyzhekova, N.A. Bernatskaya, L.N. Maslov, R. Mekhoulam, R.G. Pertwee and G.B. Stephano. Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. *Bul. Exp. Biol. Med.* 131, 523-525, 2001.
259. D.S. Ugdyzhekova, A.V. Krylatov, N.A. Bernatskaya, L.N. Maslov, R. Mechoulam and R.G. Pertwee. Activation of cannabinoid receptors decreases the area of ischemic myocardial necrosis. *Bul. Exp. Biol. Med.* 2, 125-126, 2002.
260. A.V. Krylatov, R.V. Uzhachenko, L.N. Maslov, N.A. Bernatskaya, A. Makriyannis, R. Mechoulam, R.G. Pertwee, O.M. Sal'nikova, J.B. Stefano and Yu.B. Lishmanov. Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: a possible mechanism. *Bul. Exp. Biol. Med.* 2, 122-124, 2002.
261. R. Mechoulam, D. Panikashvili and E. Shohami. Cannabinoids and brain injury: therapeutic implications. *Trends Mol. Med.* 8, 58-61 (2002).
262. E.M. Berry and R. Mechoulam. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. *Pharmacol. Ther.* 95, 185-190 (2002).

263. R. Mechoulam. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 66,93-99 (2002).

264. L. A. Parker, R. Mechoulam and C. Schlievert. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. *NeuroReport*, 13, 567-70 (2002).

265. F. Fezza, T. Bisogno, A. Minassi, G. Appendino, R. Mechoulam, V. Di Marzo. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. *FEBS Lett.* 513, 294-298, 2002.

266. R. Mechoulam, M. Spatz and E. Shohami. Endocannabinoids and neuroprotection. *Science. (STKE, Signal Transduction Knowledge Environment, Electronic Review)* 23 April, 2002.

267. K. Laine, K. Jarvinen, A. Breuer, R. Mechoulam and T. Jarvinen. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. *Inv. Ophthalmol. Vis. Sci.* 43, 3216-3222 (2002).

268. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, W.A. Devane, C.C. Felder, M. Herkenham, K. Mackie, B.R. Martin, R. Mechoulam and R.G. Pertwee. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol. Rev.* 54, 161-202, 2002.

269. R. Mechoulam and L. Hanus. Cannabidiol: An overview of some chemical and pharmacological aspects. Part I: Chemical Aspects. *Chem. Phys. Lipids* 121, 35-43 (2002).

270. V. Di Marzo, L. De Petrocellis, T. Bisogno, A. Berger and R. Mechoulam. Biology of endocannabinoids. In: *Biology of Marijuana from Gene to Behavior*. Ed. E.S. Onaivi. Publishers Taylor and Francis, 2002, pp. 125-173.

271. R. Mechoulam, L.A. Parker and R. Gallily. Cannabidiol: An overview of some pharmacological aspects. *J. Clin. Pharmacol.* 42, 11S-19S (2002).

272. R. Mechoulam. Peering through the smoke. Book review of "Understanding Marijuana: A New Look at Scientific Evidence" by Mitch Earleywine, Oxford Univ. Press. *Nature* 419, 670-671, 2002.

273. R. Mechoulam. Book reviews of:

- H.D. Neuwinger. African Traditional Medicine. A Dictionary of Plant Use and Applications. Medpharm Publ. 2000. Israel J. Plant Sciences, 49, 241-242 (2001).
- C. Kletter and M. Kriechbaum. Tibetan Medicinal Plants. Medpharm Publ. 2001. Israel J. Plant Sciences, 50, 84-85 (2002).

274. L.A. Parker, R. Mechoulam, C. Schlievert, L. Abbot, M.L. Fudge and P. Burton. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. *Psychopharmacol.* 166, 156-162 (2003).

275. E. Fride, A. Foox, E. Rosenberg, M. Faigenboim, V. Cohen, L. Barda, H. Blau and R. Mechoulam. Milk intake and survival in newborn cannabinoid CB₁ receptor knockout mice: evidence for a "CB₃" receptor. *Eur. J. Pharmacol.* 461, 27-34, (2003).

276. R. Gallily, T. Even-Chen, G. Katzavian, D. Lehmann, A. Dagan and R. Mechoulam. γ -Irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. *Leukemia & Lymphoma* 44, 1767-1773 (2003).

277. R. Mechoulam and L. Parker. Cannabis and alcohol – a close friendship. *Trends Pharmacol. Sci.* 24, 266-268 (2003).

278. L. Hanus, Y. Avraham, D. Ben-Shushan, O. Zolotarev, E.M. Berry and R. Mechoulam. Short term fasting and prolonged semistarvation have opposite effect on 2-AG levels in mouse brain. *Brain Res.* 983, 144-151 (2003).

279. R.R. Lekker, N. Gai, R. Mechoulam and H. Ovadia. Drug-induced hypothermia reduces ischemic damage. Effect the cannabinoid HU-210. *Stroke* 34, 2000-2006 (2003).

280. Y. Gilgun-Sherki, E. Melamed, R. Mechoulam and D. Offen. The CB1 cannabinoid receptor agonist, HU-210, reduced levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. *Pharmacol. & Toxicol.* 93, 66-70 (2003).

281. L.A. Parker and R. Mechoulam. Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. *Integr. Physiolog. Behav. Sci.* 38, 134-146 (2003).

282. R. Mechoulam and A.H. Lichtman. Stout guards of the central nervous system. *Science* 302, 65-66 (2003).

283. M. Lodzki, B. Godin, L. Rakou, R. Mechoulam, R. Gallily and E. Touitou. Cannabidiol – transdermal delivery and anti-inflammatory effect in a murine model. *J. Controlled Release*, 93, 377-387 (2003).

284. R.M. McCarron, E. Shohami, D. Panikashvili, Y. Chen, S. Golech, A. Strasser, R. Mechoulam, M. Spatz. Antioxidant properties of the vasoactive endocannabinoid, 2-arachidonoyl glycerol (2-AG). *Acta Neurochir. (Suppl)* 86, 271-275 (2003).

285. L.A. Parker, M. Kwiatkowska, P. Burton and R. Mechoulam. Effect of cannabinoids on lithium-induced vomiting in the *Suncus murinus* (house musk shrew). *Psychopharmacol.* 171, 156-161 (2004).

286. P.F. Sumariwalla, R. Gallily, S. Tchilibon, E. Fride, R. Mechoulam and M. Feldmann. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with anti-inflammatory properties in murine collagen-induced arthritis. *Arthritis & Rheumatism* 50, 985-998 (2004).

287. M. Kwiatkowska, L.A. Parker, P. Burton and R. Mechoulam. A comparative analysis of the potential cannabinoids and ondansetron to suppress cisplatin-induced emesis in the *Suncus murinus* (house musk shrew). *Psychopharmacol.* 174, 254-259 (2004).

288. L. Parker, P. Burton, R. Sorge, C. Yakiwchuk and R. Mechoulam. Effect of low doses of Δ^9 -tetrahydrocannabinol and cannabidiol on the extinction of cocaine- and amphetamine-induced conditioned place preference learning in rats. *Psychopharmacol.* 174, 360-366 (2004).

289. N. Kogan, R. Rabinowitz, P. Levi, D. Gibson, P. Sandor, M. Schlesinger and R. Mechoulam. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. *J. Med. Chem.* 47, 3800-3806 (2004).

290. R. Mechoulam. Guest Editorial. *Neuroendocrinol. Lett.* 25, 11-12 (2004).

291. R. Mechoulam. Preface to book 'Recent advances in pharmacology and physiology of cannabinoids', Editor Tibor Wenger, Research Signpost, Kerala, 2004.

292. R. Mechoulam and L. Hanus. The cannabinoid system: from the point of view of the chemist. In *Marijuana and Madness*, Editors D. Castle and R. Murray, Cambridge University Press, 2004, pp 1-18.

293. S. Golech, R.M. McCarron, Y. Chen, J. Bembry, F. Lenz, R. Mechoulam, E. Shohami and M. Spatz. Human brain endothelium: co-expression and function of vanilloid and endocannabinoid receptors. *Molecular Brain Research* 132, 87-92 (2004).

294. P.F. Sumariwalla, M. Feldmann, R. Gallily and R. Mechoulam. Reply to Letter to the Editor by Burstein and Zurier. *Arthritis and Rheumatism*, 50, 5079-5080 (2004).

295. E. Fride, C. Feigin, D.E. Ponde, A. Breuer, L. Hanus, N. Arshavsky, R. Mechoulam. (+)-Canabidiol analogues which bind to the cannabinoids receptors but exert peripheral activity only. *Eur. J. Pharmacol.* 506, 179-188 (2004).

296. M. Maccarrone, E. Fride, T. Bisogno, M. Bari, M.G. Cascio, N. Batista, A. Finazzi Agro, R. Suris, R. Mechoulam, V. Di Marzo. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. *Mol Human Reproduction* (in press).

297. R. Mechoulam. Preface to *Handbook of Experimental Pharmacology*, v.168, *Cannabinoids*. 2005. Editor R. Pertwee. (in press).

298. I. Lastres-Becker, F. Molina-Holgado, J.A. Ramos, R. Mechoulam, J. Fernandez-Ruiz, Cannabinoids provide neuroprotection against 6-

hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. *Neurobiol. Disease* (in press).

299. R. Mechoulam, P.F.Sumariwalla, M.Feldmann and R.Gallily. Cannabinoids in models of chronic inflammatory conditions. *Phytochemistry Reviews* (in press).

300. D. Panikashvili, R. Mechoulam, V. Trembovler, S. Beni, A. Alexandrovitch and E. Shohami. CB₁ cannabinoid receptors: involvement in neuroprotection through blood brain barrier protection and NF- κ B inhibition. *J. Central Blood Flow Metabolism* (in press).

301. Y.Avraham, A.Ben Menachem, A.Okun, O.Zlotarav, N.Abel, R.Mechoulam, E.M.Berry. Effect of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity and cognitive index in mice (in press).

302. L. Hanus, S.Tchilibon, D.E.Ponde, A.Breuer, E.Fride, R.Mechoulam. Enantiomeric cannabidiol derivatives: Synthesis and binding to cannabinoids receptors. *Org. Biomol. Chem.* (in press)

SYNTHESIS OF THE INDIVIDUAL, PHARMACOLOGICALLY DISTINCT, ENANTIOMERS OF A
TETRAHYDROCANNABINOL DERIVATIVE

Raphael Mechoulam*, Naftali Lander, Aviva Breuer and Jamal Zahalka

Department of Natural Products, Hebrew University Medical Faculty, Jerusalem
91120, Israel.


(Received 11 April 1990)

Abstract: The individual enantiomers of the 1,1-dimethylheptyl homolog of 7-hydroxy- Δ^6 -tetrahydrocannabinol, (1) and (2a), which exhibit distinct pharmacological profiles, have been obtained with very high e.e. by synthesis from the antipodes of myrtenol.

The 1,1-dimethylheptyl (DMH) homolog of [3R,4R]-7-hydroxy- Δ^6 -tetrahydrocannabinol (1) is a very potent psychotropic agent with a hashish type (cannabimimetic) profile of activity. Depending on the animal test used, it is 70-800 times more potent than the natural [3R,4R]- Δ^1 -tetrahydrocannabinol ([3R,4R]- Δ^1 -THC) (3).¹ By contrast the DMH homolog of [3S,4S]-7-hydroxy- Δ^6 -THC (2a) shows practically no cannabimimetic activity (as measured in four different

laboratories) in various animal tests in doses up to several thousand times higher than the ED₅₀ of the [3R,4R] enantiomer (1).¹ However (2a) prevents vomiting in pigeons, treated with the strongly emetic anticancer drug cisplatin.² It also acts as a functional N-methyl-D-aspartate (NMDA) receptor blocker. It binds to sites distinct from those of other non-competitive NMDA antagonists.³ It is also a potent blocker of NMDA-induced tremor, seizures and lethality in mice,³ and may therefore prove useful as a drug against NMDA-receptor mediated neurotoxicity. These results indicate that non-cannabimimetic THC-type compounds with [3S,4S] configuration have considerable therapeutic potential.

We report now the synthesis of (1) and (2a). A central aim of our approach was to achieve very high e.e. in order to make possible eventual therapeutic use of the [3S,4S] enantiomer, as the presence of traces of the [3R,4R] enantiomer could lead to undesirable side effects. The synthesis follows an approach previously used by us for the preparation of (3).⁴ The few THC-type enantiomeric pairs synthesized so far have not shown high pharmacological stereospecificity;⁵ however their e.e. have not been reported, and are presumably not higher than the e.e. of their starting materials (92-98% in the case of α -pinene used in the synthesis of THC).



[1S,5R]-Myrtenol (4a), $[\alpha]_D + 47.5$ (neat), obtained by oxidation of commercial α -pinene, (Aldrich), $[\alpha]_D + 50.7$ (neat), was esterified with pivalyl chloride to the ester (4b) which, on oxidation with anhydrous sodium chromate, at 35°C for 72 hours in acetic acid-acetic anhydride gave, after chromatography on silica gel, 4-oxo-myrtanyl pivalate (5), 30%, m.p. 42-43 (from pentane); $[\alpha]_D + 165$ (CHCl_3); λ_{max} (EtOH) 250 nm (ϵ 6000); ν_{max} (CHCl_3) 1730 and 1670 cm^{-1} ; δ (CDCl_3) 4.72 ($\text{CH}_2\text{-O}$), 5.84 (C=CH). Reduction of (5) with lithium tri-*tert*-butoxyaluminohydride in dry tetrahydrofuran led to 4-hydroxy-myrtanyl pivalate (6) which, without further purification, was condensed with 5-(1,1-dimethylheptyl)-resorcinol in dry methylene chloride in the presence of boron trifluoride etherate at -20°C. Silica gel chromatography (elution with 10% ether in petroleum ether) gave predominantly the pivalate ester (2b), 50%. Compound (2b) presumably is formed through the intermediate (7), which can be isolated if the condensation reaction is done with *p*-toluene sulphonic acid, rather than with boron trifluoride etherate. Reduction of (2b) with lithium aluminum hydride led to (2a), 96%, m.p. 141-2°C (from pentane), $[\alpha]_D + 227$ (CHCl_3), δ (CDCl_3) 6.40, 6.25 (2 arom H's), 5.6 (C=CH), 4.09 ($\text{CH}_2\text{-O}$). The same reaction sequence, starting with commercial [1R,5S]-myrtenol (Aldrich) $[\alpha]_D - 57.7$, (neat) gave (1), m.p. 141-2°C, $[\alpha]_D -226$ (CHCl_3). The enantiomeric purity of thrice recrystallized (1) and (2a) was established by h.p.l.c. analysis of the diastereoisomeric bis (MTPA) esters obtained by reaction with (S)-(+)- α -methoxy- α -(trifluoromethyl) phenyl-acetyl (MTPA) chloride.⁶ The e.e. of (1) and (2a) was found to be higher than 99.8%.⁷ This high degree of enantiomeric purity is evidenced also by their distinct binding to a cannabinoid receptor: compound (1) binds with an affinity circa 1500 times higher than the

enantiomeric (2a).⁸ The sharply contrasting pharmacologic behavior of (1) and (2a) mentioned above is also indicative of their enantiomeric purity. The high e.e. achieved is probably due to the easy crystallization of the intermediate oxo-esters (5, in the synthesis of 2a) and of the final products (1 and 2a). The Δ^1 isomer of (1) has recently been prepared via a different synthetic route.⁹

The above results show that [3S,4S]-THC-type compounds (such as 2a) can be obtained with very high e.e. and can thus be regarded as promising pharmaceutical entities.¹⁰

References and Notes

1. R. Mechoulam, J.J. Feigenbaum, N. Lander, M. Segal, T.U.C. Järbe, A.J. Hiltunen, and P. Consroe, *Experientia*, 1988, **44**, 782; P.J. Little, D.R. Compton, R. Mechoulam, and B. Martin, *Pharmacol. Biochem. Behav.*, 1989, **32**, 661; T.U.C. Järbe, A.J. Hiltunen, and R. Mechoulam, *J. Pharmacol. Exp. Ther.*, 1989, **250**, 1000. The synthesis reported now has been presented at a meeting of the US National Institute on Drug Abuse, R. Mechoulam, N. Lander, M. Srebnik, A. Breuer, M. Segal, J.J. Feigenbaum, T.U.C. Järbe and P. Consroe, *NIDA Research Monograph* 1987, **79**, 15.
2. J.J. Feigenbaum, S.A. Richmond, Y. Weissman, and R. Mechoulam, *Eur. J. Pharmacol.*, 1989, **169**, 159.
3. J. Feigenbaum, F. Bergmann, S.A. Richmond, R. Mechoulam, V. Nadler, Y. Kloog, and M. Sokolovsky, *Proc. Nat. Acad. Sci.*, 1989, **86**, 9584.
4. R. Mechoulam, P. Braun, and Y. Gaoni, *J. Amer. Chem. Soc.*, 1972, **94**, 6159.
5. R.K. Razdan, *Pharmacol. Revs.*, 1986, **38**, 75.
6. J.A. Dale, D.L. Dull, and H.S. Mosher, *J. Org. Chem.*, 1969, **34**, 2543.
7. H.p.l.c.: column, 250-4 Lichrospher Si 60 (5 μ m) cartridge (Merck, Germany); solvent, 95:5 n-hexane:ethyl acetate; flow, 1 ml/min ; detector (uv) 270 nm. Bis (MPTA) ester of (1):Rt, 12.5 min; bis (MPTA) ester of (2a):Rt, 15.6 min. N.m.r.: δ (CDCl_3):bis (MPTA) ester of (1), 3.52, 3.78 (2 OCH_3 groups); bis (MPTA) ester of (2), 3.53, 4.50 (2 OCH_3 groups).
8. A.C. Howlett, T.M. Champion, G.H. Wilken, and R. Mechoulam, *Neuropharmacol.*, 1990, **29**, 161.
9. C. Siegel, P.M. Gordon and R.K. Razdan, *J. Org. Chem.*, 1989, **54**, 5428.
10. All crystalline compounds gave elemental analyses consistent with structural assignments. All new compounds exhibited satisfactory spectral data.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.